Ketan Patel, M.D.

ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, ABK holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique, breakthrough embolotherapy products. Learn more at www.abkmedical.com.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. Learn more at www.aclaristx.com.

Amphora Medical was a medical device technology company developing minimally invasive products to restore the quality of life of people suffering from Overactive Bladder Syndrome.

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Learn more at www.avalynpharma.com.

AvenCell derives its name from the French word “avenir” to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.

Learn more at avencell.com.

Avivomed, is a medical device company developing innovative neuromodulation technology to treat large disease populations.  Learn more at www.avivomed.com.

b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.

Learn more at b1.co.

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Learn more at www.bicara.com

BioConnect Systems was a medical device company that developed a CE-Marked product for improving dialysis access  surgery.

Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited. Learn more at www.caplinpoint.net.

Cipla Health focuses on developing and commercializing products in the consumer healthcare and over-the-counter categories. Learn more at www.ciplahealth.in.

Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to lower the risks of pregnancy and premature births worldwide. We are currently developing the world’s first treatment for preeclampsia, which affects more than 10 million women every year. Learn more at www.comanchebiopharma.com.

Engrail Therapeutics is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience. Their purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases.
Learn more at www.engrail.com.

Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India*) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bio-reactor capacities ranging from 20 litres to 2000 litres.

Learn more at enzene.com.

Eywa is a global generic pharmaceutical company engaged in research and development, manufacture, marketing, sale, and distribution of generic finished dosage formulations. Learn more at www.eywapharma.com.

Immuneel is a pioneering clinical stage start-up company leading the change in cell & gene therapies & personalized immunotherapy for patients in India. Headquartered in Bengaluru, Karnataka, India, Immuneel is a research-led, fully integrated cell & gene therapies company committed to bringing breakthrough cancer treatments to India, affordably & build a portfolio of next generation cell therapies. Learn more at www.immuneel.com.

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. In July 2024, Invetx was acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business. Learn more at www.invetx.com.

Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Ivenix was acquired by Fresenius Kabi in 2022.

Laurus Labs (NSE:LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. Learn more at www.lauruslabs.com.

Medwell Ventures Private Unlimited (“Medwell”) is an operator of specialty home healthcare services in India.

Menlo Therapeutics Inc. (NASDAQ: MNLO) is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.

NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.

NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. Learn more at https://nflection.com/.

OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.  Learn more at www.oziva.in.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children’s medicines to provide Chinese children and families with high-quality and affordable treatment options.

Learn more at pediatrixtherapeutics.com.

Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.

Tetraphase (NASDAQ: TTPH)  is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVA^TM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.

Trivitron Healthcare is India’s largest, national wholesale distributor and after-sales support provider of medical equipment and devices. Learn more at www.trivitron.com.

Vicept Therapeutics is a dermatology specialty pharmaceutical company developing a topical prescription product for the treatment of the chronic skin condition, Rosacea. Vicept Therapeutics was acquired by Allergan.